Skip to main content

New Drug Approvals 2013 - Pt. XXIV - Sofosbuvir (Sovaldi ™)





ATC code (stem): J05AB
Wikipedia: Sofosbuvir
ChEMBL: CHEMBL1259059

On December 6, 2013, the FDA approved sofosbuvir for the treatment of patients with chronic hepatitis C infection. Sofosbuvir is intended for use as a component in combination treatments, depending on the type of hepatitis C either alongside Ribavirin alone, or in combination with both Ribavirin and peginterferon-alpha. Earlier in 2013, the FDA had already approved
Simeprevir for the treatment of this condition.

Hepatitis C is an infectious disease that affects primarily the liver and is caused by the hepatitis C virus (HCV), which belongs to the family of Flaviviridae and has a positive sense single stranded RNA genome of 9,600 nucleotides. Infection is mainly by blood-to-blood contact, through sharing or reuse of syringes or unsterilized medical equipment. Initially, the infection progresses without symptoms, and only becomes apparent in the chronic stages when liver damage leads to symptoms such as bleeding, jaundice, liver cancer and hepatic encephalopathy.

Sofosbuvir is a nucleotide analog inhibitor of the viral RNA polymerase (NS5b, Uniprot genome polyprotein: P26664, 2421-3011, PDB 3hkw). Viral RNA polymerases differ significantly from eukaryotic and bacterial polymerases both in sequence and three-dimensional structure. Thus, sofosbuvir inhibits only the amplification of the viral RNA genome and not endogenous transcription in the host organism by entering the polymerase as a substrate and terminating the transcript chain. The IC50 measured against NS5b ranged between 0.7 and 2.6 micro-molar, depending on the genotpye of the HCV isolate.

Structure of HCV NS5b, genotype 1a generated in pymol from PDB 3hkw.
 Sofosbuvir is a prodrug that is converted to the active form through a mono-phosphorylated intermediate. In contrast to other nucleotide analog inhibitors, the intermediate is formed in a step that cleaves off the groups attached to the phosphate group already present in sofosbuvir. This step is a lot faster than the enzymatic addition of a phosphate group that is required with other nucleotide analogs. The enzymes catalyzing this initial step include the lysosomal protective protein (Uniprot P10619), liver carboxylesterase 1 (Uniprot P23141) and Hint1 (Uniprot P49773). [1]



 Canonical SMILES: CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)Oc3ccccc3 
Std-InChI: InChI=1S/C22H29FN3O9P/c1-13(2)33-19(29)14(3)25-36(31,35-15-8-6-5-7-9-15)32-12-16-18(28)22(4,23)20(34-16)26-11-10-17(27)24-21(26)30/h5-11,13-14,16,18,20,28H,12H2,1-4H3,(H,25,31)(H,24,27,30)/t14-,16+,18+,20+,22+,36-/m0/s1
Std InChI key: TTZHDVOVKQGIBA-IQWMDFIBSA-N

Sofosbuvir is an off-white crystalline substance that is slightly soluble in water. The molecular weight and logP are 529.45 Da and 0.92, respectively. Note the relatively low logP charateristic of nucleotide analog compounds.

The recommended daily dose of sofosbuvir is 400mg in a single tablet. Peak plasma concentration of the active metabolite are reached after 30-120 minutes post administration. The clearance is primarily through the kidney, with a half-life of 0.4 hours for sofosbuvir and 27 hours for its metabolite.  Sofosbuvir is a substrate of P-gp, and therefore inducers of P-gp, such as rifampicin and St John's wort are contraindicated for use with sofosbuvir.

Reported side effects of sofosbuvir include fatigue, headache, nausea, insomnia and anemia.

Sofosbuvir is marketed by Gilead under the name Sovaldi.

References:
[1] Murakami E, Tolstykh T, Bao H, Niu C, Steuer HMM, Bao D, Chang W, Espiritu C, Bansal S, Lam AM, Otto MJ, Sofia MJ, Furman P a: Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977. J. Biol. Chem. 2010, 285:34337–47.

Comments

Popular posts from this blog

New SureChEMBL announcement

(Generated with DALL-E 3 ∙ 30 October 2023 at 1:48 pm) We have some very exciting news to report: the new SureChEMBL is now available! Hooray! What is SureChEMBL, you may ask. Good question! In our portfolio of chemical biology services, alongside our established database of bioactivity data for drug-like molecules ChEMBL , our dictionary of annotated small molecule entities ChEBI , and our compound cross-referencing system UniChem , we also deliver a database of annotated patents! Almost 10 years ago , EMBL-EBI acquired the SureChem system of chemically annotated patents and made this freely accessible in the public domain as SureChEMBL. Since then, our team has continued to maintain and deliver SureChEMBL. However, this has become increasingly challenging due to the complexities of the underlying codebase. We were awarded a Wellcome Trust grant in 2021 to completely overhaul SureChEMBL, with a new UI, backend infrastructure, and new f

A python client for accessing ChEMBL web services

Motivation The CheMBL Web Services provide simple reliable programmatic access to the data stored in ChEMBL database. RESTful API approaches are quite easy to master in most languages but still require writing a few lines of code. Additionally, it can be a challenging task to write a nontrivial application using REST without any examples. These factors were the motivation for us to write a small client library for accessing web services from Python. Why Python? We choose this language because Python has become extremely popular (and still growing in use) in scientific applications; there are several Open Source chemical toolkits available in this language, and so the wealth of ChEMBL resources and functionality of those toolkits can be easily combined. Moreover, Python is a very web-friendly language and we wanted to show how easy complex resource acquisition can be expressed in Python. Reinventing the wheel? There are already some libraries providing access to ChEMBL d

LSH-based similarity search in MongoDB is faster than postgres cartridge.

TL;DR: In his excellent blog post , Matt Swain described the implementation of compound similarity searches in MongoDB . Unfortunately, Matt's approach had suboptimal ( polynomial ) time complexity with respect to decreasing similarity thresholds, which renders unsuitable for production environments. In this article, we improve on the method by enhancing it with Locality Sensitive Hashing algorithm, which significantly reduces query time and outperforms RDKit PostgreSQL cartridge . myChEMBL 21 - NoSQL edition    Given that NoSQL technologies applied to computational chemistry and cheminformatics are gaining traction and popularity, we decided to include a taster in future myChEMBL releases. Two especially appealing technologies are Neo4j and MongoDB . The former is a graph database and the latter is a BSON document storage. We would like to provide IPython notebook -based tutorials explaining how to use this software to deal with common cheminformatics p

Multi-task neural network on ChEMBL with PyTorch 1.0 and RDKit

  Update: KNIME protocol with the model available thanks to Greg Landrum. Update: New code to train the model and ONNX exported trained models available in github . The use and application of multi-task neural networks is growing rapidly in cheminformatics and drug discovery. Examples can be found in the following publications: - Deep Learning as an Opportunity in VirtualScreening - Massively Multitask Networks for Drug Discovery - Beyond the hype: deep neural networks outperform established methods using a ChEMBL bioactivity benchmark set But what is a multi-task neural network? In short, it's a kind of neural network architecture that can optimise multiple classification/regression problems at the same time while taking advantage of their shared description. This blogpost gives a great overview of their architecture. All networks in references above implement the hard parameter sharing approach. So, having a set of activities relating targets and molecules we can tra

Using ChEMBL activity comments

We’re sometimes asked what the ‘activity_comments’ in the ChEMBL database mean. In this Blog post, we’ll use aspirin as an example to explain some of the more common activity comments. First, let’s review the bioactivity data included in ChEMBL. We extract bioactivity data directly from   seven core medicinal chemistry journals . Some common activity types, such as IC50s, are standardised  to allow broad comparisons across assays; the standardised data can be found in the  standard_value ,  standard_relation  and  standard_units  fields. Original data is retained in the database downloads in the  value ,  relation  and  units  fields. However, we extract all data from a publication including non-numerical bioactivity and ADME data. In these cases, the activity comments may be populated during the ChEMBL extraction-curation process  in order to capture the author's  overall  conclusions . Similarly, for deposited datasets and subsets of other databases (e.g. DrugMatrix, PubChem), th